[1] Chen M, Daha MR, Kallenberq CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010, 34(3):276-86.
[2] Coutrue J, Silverman ED. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus.Curr Opin Rheumatol. 2016,28(5):488-96.
[3] Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol.2001,2(9):764-6.
[4] Mok CC, Lau CS.Pathogenesis of systemic lupus erythematosus.J Clin Pathol. 2003, 56(7):481-90.
[5] He J,Li Z. An era of biological treatment in systemic lupus erythematosus.Clin Rheumatol.2018 Jan;37(1):1-3.
[6] Gatto M,Saccon F, et al.Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis.J Autoimmun.2016 Nov;74:94-105.
[7] Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus complements deficiency and apoptosis. Adv Immunol (2000) 76:227–324.
[8] O’Neil KM. Complement deficiency. Clin Rev Allergy Immunol (2000) 19:83.
[9] Laich A, Sim RB. Cross-talk between the human complement classical and alternative pathways: evidence for a C4bBb “hybrid” C3 convertase. Mol Immunol (2001) 38:105.
[10] Perazzio SF, Silva NP, et al. Mild and moderate mannose binding lectin deficiency are associated with systemic lupus erythematosus and lupus nephritis in Brazilian patients.Rev Bras Reumatol, 2016, 56(3):220-7.
[11]Panda AK,Parida JR, et al. Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity.Arthritis Res Ther, 2012, 14(5):R218.
[12] Qiao Q, Teng X, Wang N, Lu R, Guo L, et al. A novel CRIg-targeted complement inhibitor protects cell from complement damage. FASEB J, 2014, 28(11):4986-99.
[13] Trouw LA,Pickering MC,Blom AM.The complement system as a potential therapeutic target in rheumatic disease.Nat Rev Rheumatol,2017,13(9):538-547.
[14] Pouw RB, Vredevooqd DW, Kuipers TW, et al. Of mice and men: The factor H protein family and complement regulation. Mol Immunol, 2015,67(1):12-20.
[15]Bajema, IM, Wilhelmus, S , Alpers, CE, et al. Revision of the ISN/RPS classification for lupus nephritis: modified NIH activity and chronicity indices and clarification of definitions. Kidney Int. 2018 Apr;93(4):789-796.
[16] Lieberman LA, Mizui M, Nalbandian A, et al. Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. Immunol, 2015, 160(2):286-91.
[17] He JQ, Wiesmann C, van Lookeren Campagne M. A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol,2008,45(16):4041-7.
[18] Wang Y,Hu Q,Madri JA, et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antiboy specific for complement component C5.Proc Natl.1996 Aug 6;93(16):8563-8.
[19] Sciascia S, Radin M, et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int.2017,37(8):1249-1255.
[20] Barilla-Labarca M L, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases.Clin Immunol, 2013,148(3):313-321.
[21]Lattanzi B, Consolaro A, Solari N, et al. Measure of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI).Arthritis Care Res.2011,Nov;63.
[22] Irvine KM, Banh X, et al. CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites.JCI Insight.2016 Jun 2;1(8):e86914.
[23] Struz F, Muller GA. The progresson of chronic renal disease. Nephron,1995,69:371-379.
[24] Anders H J, Fogo A B. Immunopathology of lupus nephritis[J]. Semin Immunopathol, 2014, 36(4):443-459.
[25] Lorenz G, Desai J, Anders H J. Lupus nephritis: update on mechanisms of systemic autoimmunity and kidney immunopathology[J]. Curr Opin Nephrol Hypertens, 2014, 23(3):211-217.
[26] Lindquist J A, Hildebrandt J, Philipsen L, et al. Immune complexes and complexity: investigating mechanisms of renal disease[J]. Int Urol Nephrol, 2017,49(4):735-739.
[27] Gackler A, Rohn H, et al. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant. 2018,9.